Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advertisement
Zachary BessetteAdvanced Urothelial Carcinoma | January 3, 2023
Membranous NECTIN-4 expression is frequently decreased or absent altogether in metastatic urothelial carcinoma tissue.
Read More
Emily MenendezAdvanced Urothelial Carcinoma | December 29, 2022
After five years follow-up, new results show the durability of response to pembrolizumab for metastatic urothelial carcinoma.
Zachary BessetteAdvanced Urothelial Carcinoma | December 12, 2022
A newly published case report may signify a promising novel antitumor strategy in locally advanced or metastatic UC.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Shilpa Gupta, MD, discusses the impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Enfortumab vedotin led to longer OS than chemotherapy in previously treated urothelial carcinoma.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Most patients with locally advanced or metastatic urothelial carcinoma did not receive first-line systemic therapy.
Leah LawrenceAdvanced Urothelial Carcinoma | October 18, 2022
FGFR-directed therapy had similar efficacy to chemotherapy in treating advanced or metastatic urothelial carcinoma.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Enfortumab vedotin ranks first in efficacy among 6 treatments for metastatic urothelial cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Shilpa Gupta, MD, discusses treatments for cisplatin-ineligible patients with advanced bladder cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Women with advanced urothelial carcinoma have a significantly greater risk of progression after chemotherapy than men.
Cecilia BrownAdvanced Urothelial Carcinoma | October 14, 2022
Lymphovascular invasion in upper tract urothelial carcinoma puts patients at higher risk for recurrence and mortality.
Cecilia BrownAdvanced Urothelial Carcinoma | September 22, 2022
The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.
Cecilia BrownAdvanced Urothelial Carcinoma | September 22, 2022
Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.
Cecilia BrownAdvanced Urothelial Carcinoma | September 22, 2022
Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | September 22, 2022
Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.
Leah LawrenceESMO 2022 | September 16, 2022
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Advertisement
Advertisement
Advertisement